Subscribe To
MLAB / Bull of the Day: Mesa Labs (MLAB)
MLAB News
By Zacks Investment Research
September 22, 2023
Bear of the Day: Mesa Labs (MLAB)
Mesa Labs ( MLAB ) is a small-cap medical provider of quality control monitoring and validation instruments serving niche markets in healthcare, indus more_horizontal
By GlobeNewsWire
September 13, 2023
Mesa Laboratories, Inc. to Announce Second Quarter Results on November 6, 2023
LAKEWOOD, Colo., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the se more_horizontal
By GlobeNewsWire
June 21, 2023
Mesa Laboratories, Inc. to Announce First Quarter Results on August 3, 2023
LAKEWOOD, Colo., June 21, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fir more_horizontal
By Zacks Investment Research
May 25, 2023
Mesa Labs (MLAB) Q4 Earnings and Revenues Miss Estimates
Mesa Labs (MLAB) came out with quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $1.98 per share. This compares to earnin more_horizontal
By Seeking Alpha
February 27, 2023
Mesa Laboratories: Divisional Growth, Valuations Supportive Of Hold
In Q3, Mesa Laboratories reported mixed results throughout the P&L with soft bottom-line fundamentals. FCF growth still lumpy with contraction in divi more_horizontal
By Zacks Investment Research
February 14, 2023
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now. more_horizontal
By Zacks Investment Research
February 13, 2023
Is Mesa Labs (MLAB) a Solid Growth Stock? 3 Reasons to Think "Yes"
Mesa Labs (MLAB) is well positioned to outperform the market, as it exhibits above-average growth in financials. more_horizontal
By Zacks Investment Research
February 1, 2023
What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?
Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales. more_horizontal